Novartis biosimilar copycat takes aim at Amgen's drug Enbrel

ZURICH (Reuters) – The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster Enbrel drug, the Swiss drugmaker said on Friday.


Source: ReuterBusiness

Related posts